After over three decades of being acknowledged as a crucial molecule in pulmonary pathology, cutting-edge approaches have shown new ways that EGFR may function as a marker and a component in determining treatment, both in the advanced and early stages of NSCLC. This evidence concerns the gene EGFR and non-small cell lung carcinoma.